fb-pixel Skip to main content

Vertex strikes deal with Seaport neighbor to develop therapies for rare muscle disease

The partnership is focused on, but not limited to, an experimental drug that Entrada was already developing for myotonic dystrophy type 1, often called DM1.

Vor Biopharma says first patient given its gene editing therapy for leukemia is in remission
The clinical trial of the therapy was delayed due to the COVID-19 pandemic, and the firm faced difficulties finding volunteers willing to participate.

Biotech cofounded by Dana-Farber scientists launches with $81m for new approach to drugs
The focus on boosting good proteins, rather than getting rid of bad ones, flips the traditional drug discovery model and opens up a swathe of potential drug targets long overlooked by the biotech industry.

Pfizer partners with tiny Cambridge startup to develop new COVID pills
Clear Creek and Pfizer will embark on a research collaboration to make new drugs that inhibit a protein that the coronavirus requires for replicating.

Expanding waiver of intellectual property protections could jeopardize US biotech dominance
US leaders, including Rhode Island’s congressional delegation, must stand up for the US biotech industry as the WTO considers expanding a waiver of intellectual property protections to include COVID diagnostics and therapeutics.

Somerville and Seattle scientists use A.I. to design proteins from scratch
The field, known as de novo protein design, is attracting biologists and programmers alike, including teams at tech giants Alphabet, Meta, and Microsoft.

More Life Sciences Headlines

COMMENTARY | CAROL MALYSZ

Expanding waiver of intellectual property protections could jeopardize US biotech dominance

US leaders, including Rhode Island’s congressional delegation, must stand up for the US biotech industry as the WTO considers expanding a waiver of intellectual property protections to include COVID diagnostics and therapeutics.

Somerville and Seattle scientists use A.I. to design proteins from scratch

The field, known as de novo protein design, is attracting biologists and programmers alike, including teams at tech giants Alphabet, Meta, and Microsoft.

Study shows Alzheimer’s drug ‘moderately’ slowed cognitive decline

Despite the results, the death of a second patient in the trial may raise concerns about the experimental medicine made by Biogen and its Japanese partner, Eisai.

Boston mRNA startup raises millions to test its targeted cancer therapies

A $97 million funding round comes as anticipation builds for companies to prove that the COVID-19 vaccines were not one-hit wonders for mRNA technology.

MIT scientists invent technology to replace broken genes or upload new ones

The researchers behind the new gene editing technique also founded the secretive Watertown biotech company Tome Biosciences.

A new coronavirus variant has taken over, sparking concerns of a winter surge

So far, COVID cases don’t seem to be rising, but scientists aren’t sure if that will last. And several studies suggest that new booster shots don’t trigger strong immunity to the new variant.

Boston biotech Jnana raises $107 million and strikes second collaboration with Roche

Jnana also struck its second drug discovery collaboration with the pharma giant Roche that will earn the startup $50 million upfront plus potential milestone payments that could exceed $2 billion.

Head of MassBio trade group is out after serving just over a year

The abrupt leadership changes come at a sensitive time for MassBio, which lobbies for the state’s biotechnolology industry, a pillar of the Massachusetts economy.